Bristol Myers Squibb Reports Q1 Results, Reaffirms Guidance, and Highlights Key Pipeline Progress

summarizeSummary

Bristol Myers Squibb announced Q1 2026 financial results with revenue growth and reaffirmed full-year guidance, alongside several positive pipeline and regulatory milestones.

check_boxKey Events

• Q1 2026 Financial Performance

  Revenues increased 3% to $11.5 billion, and GAAP EPS rose 9% to $1.31. Non-GAAP EPS decreased 12% to $1.58.

• Full-Year Guidance Reaffirmed

  The company reaffirmed its 2026 financial guidance, with total revenues and non-GAAP EPS trending towards the upper end of the previously provided ranges.

• Strong Growth Portfolio Performance

  Growth Portfolio revenues increased 12% (+9% Ex-FX) to $6.2 billion, driven by products like Camzyos, Breyanzi, and Reblozyl.

• Key Pipeline & Regulatory Milestones

  Achieved multiple clinical and regulatory milestones, including FDA approval for Sotyktu in psoriatic arthritis, positive Phase 3 data for mezigdomide in multiple myeloma, and FDA approval for Opdivo in classical Hodgkin Lymphoma.

auto_awesomeAnalysis

Bristol Myers Squibb reported a 3% increase in first-quarter revenues to $11.5 billion and a 9% rise in GAAP EPS to $1.31. While non-GAAP EPS saw a 12% decline, the company reaffirmed its full-year 2026 financial guidance, with revenues and non-GAAP EPS trending towards the upper end of the ranges. This indicates management's confidence in future performance, driven by strong growth in its newer portfolio and significant advancements in its pipeline, including multiple regulatory approvals and positive clinical trial readouts. Investors should monitor the continued performance of the growth portfolio and the progression of key pipeline assets.